The American Red Cross Relieves VDI Printing Pains with UniPrint Infinity
Ahead of their appearance at the VMworld US trade show in Las Vegas, Print Virtualization software provider UniPrint.net Corp announced today the release of their latest case study: The American Red Cross (ARC). With a national network of more than 300 chapters, The American Red Cross is one of the world’s premier charitable organizations made up of workers and volunteers providing humanitarian relief both in the United States and abroad.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170824005757/en/
The ARC’s IT infrastructure includes more than 20,000 employees and 300,000 volunteers in offices, remote locations, connecting from home, or in the field in disaster zones. In 2015, their End Use Technologies Solutions (EUTS) team began their search for a virtual workspace solution that would give their users access to applications, data, and resources from any location. Immediately, printing was identified as an issue, both due to driver incompatibility being common in VDI environments, and due to the tediousness of Group Policies for printer mapping with so many remote locations and devices.
They were also looking to eliminate hardware and consolidate remote site resources back to the data center, which posed potential bandwidth issues. Additionally, the EUTS team intended on instituting a BYOD (bring-your-own-device) model which would also require a stable print management solution.
With their implementation of UniPrint Infinity™ The ARC was able to solve all of their printing challenges with one streamlined solution. The patented PDF-based Universal Printer Driver (UPD) solved the issue of printer driver incompatibility and eliminated the need for repeated and frequent vendor driver updates. Printer mapping issues were also solved with the PrintPAL utility, which allows administrators to implement broad printing policies with only a few clicks.
There was also the added benefit of reduced call volume to The ARC’s third-party service desk. Adam Flowers, Lead Solutions Architect, remarked:
“There was a reduction in helpdesk calls for printing related issues as we made improvements to our environment with UniPrint […] UniPrint saved us lots of time and headaches, and it really made our techs available to deal with higher priority issues.”
Other benefits included the flexibility of BYOD printing, as well as a reduction in bandwidth usage (and therefore a reduction in cost). UniPrint Infinity has not only helped The American Red Cross funnel more resources back into the community, but also helped staff spend less time on printing and more time focusing on making the world a better place.
“The UniPrint Infinity™ suite allows us to adapt to whatever situation our people may be in,” said Flowers. “There’s nothing we’ve been asked to do that UniPrint can’t handle.”
- Universal Printer Driver (UPD) solves incompatibility issues and reduces helpdesk calls
- PrintPAL technology eliminates the need for mapping through Group Policies
- Reduces overhead cost through printer server consolidation
- High Availability (HA) module provides enterprise wide redundancy and fault tolerance
- Resolves bandwidth issues using PDF compression to compress and encrypt print jobs
- Provides local and remote users with seamless, stable, and secure printing from any device to the nearest available printer
To learn more, check out our video interview with Adam Flowers on how UniPrint Infinity transformed American Red Cross’ IT workflow, and don’t forget to stop by Booth 1724 at VMworld US in Las Vegas Aug. 27-31 to meet the UniPrint team!
About UniPrint.net Corp
UniPrint.net Corp. is an innovative leader in printing virtualization. Their patented PDF-based software, UniPrint Infinity™, is the industry’s first truly secure enterprise printing solution for any computing environment. UniPrint Infinity replaces all manufacturer printer drivers with a single Universal Printer Driver (UPD) to promote faster, more efficient printing. Both UniPrint™ and UniPrint Infinity™ are the trademarks of UniPrint.net. All other trademarks and registered trademarks are properties of their respective owners.
Kate Bradford, 416-503-9800 x8258
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
OTEZLA® (Apremilast) Phase III Data Showed Significant Improvements in Patients with Active Behçet’s Disease with Oral Ulcers17.2.2018 21:00 | Pressemelding
Celgene Corporation (NASDAQ:CELG) today announced that data from the phase III RELIEF™ clinical trial of OTEZLA® (apremilast) in patients with active Behçet’s Disease with oral ulcers were presented in a late-breaking oral presentation at the 2018 American Academy of Dermatology (AAD) Annual Meeting. The results showed statistically significant reductions in oral ulcers with apremilast 30 mg twice daily (BID) versus placebo through week 12. OTEZLA (apremilast) is Celgene’s oral selective inhibitor of phosphodiesterase 4 (PDE4). Behçet’s Disease is a rare, chronic, multi-system inflammatory syndrome. Oral ulcers, the most common manifestation of Behçet’s Disease, can be disabling and have a substantial effect on quality of life. This study primarily evaluated the effect of apremilast on recurring oral ulcers in patients with active Behçet’s Disease who were previously treated with at least one topical or systemic medication. “Reducing oral ulcers, which are painful and can negatively im
CT-P13 (biosimilar infliximab) is comparable to reference infliximab and adalimumab in highly anticipated real-world study17.2.2018 08:00 | Pressemelding
Twelve-month data from the Personalised Anti-TNF therapy in Crohn’s disease Study (PANTS) was presented at the 13th Congress of the European Crohn’s and Colitis Organisation (ECCO). The results indicate that the clinical effectiveness, safety and immunogenicity of Celltrion Healthcare’s CT-P13 (biosimilar infliximab) in patients with Crohn’s disease (CD) is comparable to those treated with reference infliximab as well as those treated with adalimumab.1 The UK-wide, three-year prospective observational study investigated primary non-response (PNR), loss of response (LOR) and adverse drug reactions (ADR) to infliximab (reference infliximab and CT-P13) and adalimumab in 1610 CD patients. The data show comparable efficacy between CT-P13, reference infliximab and adalimumab in relation to PNR, LOR and ADR rates. In addition, at week 54, the remission rate was 39.7%, 39.0% and 32.7% for reference infliximab, CT-P13 and adalimumab treated patients, respectively.1 The PANTS study investigates
Avanti Communications HYLAS 4 Satellite Arrives in French Guiana16.2.2018 18:26 | Pressemelding
Avanti Communications Group plc (“Avanti”), a leading provider of satellite data communications services in Europe, the Middle East and Africa (“EMEA”), announces its HYLAS 4 satellite has arrived safely in French Guiana ahead of its March 2018 launch. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005586/en/ Avanti Communications HYLAS 4 Satellite Arrives in French Guiana (Photo: Business Wire) The spacecraft, built by Orbital ATK was packed and shipped at their Satellite Manufacturing Facility in Dulles, Virginia, United States and flown to French Guiana, where it was unloaded and will be taken to the Arianespace launch facilities in Kourou. HYLAS 4 uses the latest High Throughput Satellite technology, doubling Avanti's Ka-band capacity across EMEA. The latest addition to Avanti's HYLAS fleet will provide: Backhaul services for mobile network operators Wholesale broadband for ISPs Connectivity for governments (civil a
General Cable Corporation Stockholders Approve Acquisition By Prysmian Group16.2.2018 17:05 | Pressemelding
General Cable Corporation (NYSE: BGC) today announced the voting results from the Company’s special meeting of stockholders held this morning. Stockholders of General Cable approved the Company’s previously announced acquisition by Prysmian Group (BIT: PRY) for $30.00 per share in cash. A total of 38,140,754 shares, representing approximately 75.34% of the total number of shares of common stock outstanding and approximately 99% of the total votes cast, were voted in favor of the merger. Subject to regulatory approvals and other customary closing conditions, the transaction is expected to close by the third quarter of 2018. About General Cable General Cable (NYSE:BGC), with headquarters in Highland Heights, Kentucky, is a global leader in the development, design, manufacture, marketing and distribution of aluminum, copper and fiber optic wire and cable products for the energy, communications, automotive, industrial, construction and specialty segments. General Cable is one of the larges
Systemic Sclerosis World Congress:Inspirational Patient Stories Reveal the Challenging Realities of Living with Devastating Rare Disease16.2.2018 09:03 | Pressemelding
Boehringer Ingelheim today unveils a new phase of 'More Than Scleroderma: The Inside Story', and launches the new patient website www.morethanscleroderma.com. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180216005188/en/ Anna, 36, living with scleroderma (Photo: Business Wire) The global initiative highlights the importance of understanding the ‘inside story’ of each individual living with scleroderma, also known as systemic sclerosis. To coincide with the Systemic Sclerosis World Congress in Bordeaux, 15-17 February 2018, new and truly inspiring patient stories are revealed, reflecting the real-life, diverse and very moving journeys of people living with scleroderma across the world. The campaign will also be launched in the U.S. The new website www.morethanscleroderma.com features a powerful collection of photographs and video stories of people living with scleroderma across the world, revealing the life-changing impact o
Philip Morris International Recognized as a Global Top Employer for the Second Year in a Row16.2.2018 08:00 | Pressemelding
Philip Morris International Inc. (PMI) (NYSE/Euronext Paris: PM) today is recognized for the second year in a row as a Global Top Employer. This year’s certification from the Top Employer Institute is awarded to PMI teams in 44 countries, a testament to the company’s consistency and excellence in offering an enriching and dynamic work environment, and exceptional development opportunities for employees across the globe. PMI has been recognized by the Top Employer Institute for six consecutive years. This year, PMI was awarded with five regional certifications in Europe, the Middle East, Africa and, for the first time, in North America and Latin America. Additionally, Indonesia was the first PMI affiliate to be certified in Asia. “It is a proud moment for all of us at PMI,” said Charles Bendotti, PMI Senior Vice President, People and Culture. “Our success as a company relies on the men and women who come to work every day with a passion to achieve, and a willingness to learn, grow, and